Trial Profile
A Randomized, Double-blind Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Amlodipine Versus Fimasartan Monotherapy in Patients With Essential Hypertension Who Fail to Respond Adequately to Fimasartan Monotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Amlodipine/fimasartan (Primary) ; Fimasartan
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Boryung Pharmaceutical
- 24 Jul 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 18 Jun 2014 New trial record